Treatment with a GLP-1R agonist over four weeks promotes weight loss-moderated changes in frontal-striatal brain structures in individuals with mood disorders

Treatment with a GLP-1R agonist over four weeks promotes weight loss-moderated changes in frontal-striatal brain structures in individuals with mood disorders

Author Mansur, Rodrigo B. Autor UNIFESP Google Scholar
Zugman, Andre Autor UNIFESP Google Scholar
Ahmed, Juhie Google Scholar
Cha, Danielle S. Google Scholar
Subramaniapillai, Mehala Google Scholar
Lee, Yena Google Scholar
Lovshin, Julie Google Scholar
Lee, Jung G. Google Scholar
Lee, Jae-Hon Google Scholar
Drobinin, Vladislav Google Scholar
Newport, Jason Google Scholar
Brietzke, Elisa Autor UNIFESP Google Scholar
Reininghaus, Eva Z. Google Scholar
Sim, Kang Google Scholar
Vinberg, Maj Google Scholar
Rasgon, Natalie Google Scholar
Hajek, Tomas Google Scholar
McIntyre, Roger S. Google Scholar
Abstract Cognitive deficits are a core feature across psychiatric disorders. Emerging evidence indicates that metabolic pathways are highly relevant for the substrates and phenomenology of the cognitive domain. Herein, we aimed to determine the effects of liraglutide, a GLP - 1R agonist, on brain structural/volumetric parameters in adults with a mood disorder. This is the secondary analysis of a 4-week, pilot, proof-of-concept, open-label study. Participants (N=19) exhibiting impairments in executive function with either major depressive disorder (MDD) or bipolar disorder (BD) were recruited. Liraglutide 1.8 mg/day was added as an adjunct to existing pharmacotherapy. Structural magnetic resonance imaging (MRI) scanning was obtained at baseline and endpoint. Results showed that at endpoint there was significant weight loss (mean: 3.15%; p<0.001). Changes in frontal and striatal volumes were significantly correlated with changes in body mass index (BMI), indicating the weight loss was associated with volume increase in most regions (e.g. r=-0.561, p=0.042 in the left superior frontal area). After adjusting for intracranial volume, age, gender, and BMI, we observed significant changes from baseline to endpoint in multiple regions (e.g. RR: 1.011, p=0.049 in the left rostral middle frontal area). Changes in regional volumes were associated with improvement in executive function (e.g. r=0.698, p=0.003 for the right superior frontal area). Adjunctive Liraglutide results in clinically significant weight loss, with corresponding improvement in cognitive function; changes in cognitive function were partially moderated by changes in brain morphometry, underscoring the interrelationship between weight and brain structure/function. (C) 2017 Elsevier B.V. and ECNP. All rights reserved.
Keywords Mood disorders
Gtucagon-like peptide-1
Weight loss
Gray matter volume
xmlui.dri2xhtml.METS-1.0.item-coverage Amsterdam
Language English
Sponsor Brain and Cognition Discovery Foundation (BCDF)
Date 2017
Published in European Neuropsychopharmacology. Amsterdam, v. 27, n. 11, p. 1153-1162, 2017.
ISSN 0924-977X (Sherpa/Romeo, impact factor)
Publisher Elsevier Science Bv
Extent 1153-1162
Access rights Closed access
Type Article
Web of Science ID WOS:000415057600007

Show full item record


File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)




My Account